Łukasz Kałuski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Łukasz Kałuski has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Małgorzata Łobocka
Institute of Biochemistry and Biophysics of the Polish Academy of Sciences, Warsaw, Poland
2 shared publications Aleksandra Głowacka-Rutkowska
Institute of Biochemistry and Biophysics, Polish Academy of Sciences
1 shared publicationAleksandra Szczypkowska
Institute of Biochemistry and Biophysics, Polish Academy of Sciences
1 shared publicationEmil Stefańczyk
Institute of Biochemistry and Biophysics, Polish Academy of Sciences
1 shared publication- Emil Stefańczyk
Plant Breeding and Acclimatization Institute-National Research Institute, Młochów Research Centre, Młochów, Poland
1 shared publication - Ivana Mašlaňová
Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic
1 shared publication
Latest Publications
- Open Access
- 17 July 2026
- Published by Springer Nature in Microbial Cell Factories
- Vol. 25 (1)
A versatile toolset for Staphylococcus aureus gene inactivation enables testing of anti-phage defense systems in native genetic backgrounds
Functional gene analysis of Staphylococcus aureus across different strains requires the development of genetic engineering tools. In studies on phage thera
- 17 July 2026
- Published by Springer Nature in Microbial Cell Factories
- Vol. 25 (1)
Open AccessA versatile toolset for Staphylococcus aureus gene inactivation enables testing of anti-phage defense systems in native genetic backgrounds
Functional gene analysis of Staphylococcus aureus across different strains requires the development of genetic engineering tools. In studies on phage thera
- Open Access
- 11 July 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (8) , e0333224
Characterization of a novel Phietavirus genus bacteriophage and its potential for efficient transfer of modified shuttle plasmids to Staphylococcus aureus strains of different clonal complexes
Staphylococcus aureus is a significant human pathogen responsible for various nosocomial and community-acquired infections, leading to considerable morbidity and mortality worldwide. Temperate bacteriophages contribute to its virulence and facilitate the dissemination of pathogenicity traits. We isolated a novel siphovirus of the Phietavirus genus, ASZ22RN, derived from a prophage of an S. aureus clonal complex 7 strain and capable of propagating in the prophage-free laboratory strain RN4220. ASZ22RN either productively infected or lysed from without all 47 tested S. aureus clinical strains across 12 clonal complexes (CCs), demonstrating its ability to puncture their cell envelopes. When ASZ22RN was propagated in RN4220 cells harboring an S. aureus-Escherichia coli plasmid replicating via theta mode, it transduced the plasmid to plasmid-free RN4220 with low frequency. The transduction frequency increased by nearly five orders of magnitude when the plasmid contained a fragment of ASZ22RN DNA ( terS ). Most terS+ plasmid-transducing particles carried plasmid concatamers, while some carried plasmid-phage DNA hybrids, as demonstrated by DNA sequencing. Strains from all tested CCs served as recipients for transduction, regardless of the presence of type I restriction-modification enzymes targeting plasmid/phage DNA, or prophages with lysis-lysogeny switch regions conferring superinfection immunity to ASZ22RN. Our results indicate that intracellular phage defense systems do not prevent phage-mediated plasmid transfer and demonstrate a simple method for introducing plasmids constructed in E. coli into clinical S. aureus isolates. Moreover, the presence of the ASZ22RN lysis-lysogeny switch region in 21% of tested ASZ22RN-resistant strains highlights superinfection exclusion as a dominant mechanism of resistance to siphoviruses in staphylococci. IMPORTANCE: This study highlights the capacity of a newly isolated staphylococcal Phietavirus , ASZ22RN, to transfer a low-copy-number shuttle Staphylococcus aureus - Escherichia coli plasmid to various S. aureus strains representing major clonal complexes from among clinical isolates. By increasing the plasmid transduction efficiency in an ASZ22RN-specific manner, we show that the primary factor determining a given strain’s ability to be a recipient in transduction is the capacity of transducing phage to puncture the cell envelopes of this strain. This can be determined not only based on productive phage infection but also lysis from without. Major intracellular mechanisms protecting S. aureus from productive phage infection do not impede the transduction-mediated acquisition of plasmids. Moreover, the lack of phage DNA in most of the plasmid-transducing virions indicates the lack of phage contamination in most transductants. Our results offer a promising approach for developing efficient pipelines to introduce plasmids constructed in E. coli to clinical S. aureus isolates.
- 11 July 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (8) , e0333224
Open AccessCharacterization of a novel Phietavirus genus bacteriophage and its potential for efficient transfer of modified shuttle plasmids to Staphylococcus aureus strains of different clonal complexes
Staphylococcus aureus is a significant human pathogen responsible for various nosocomial and community-acquired infections, leading to considerable morbidity and mortality worldwide. Temperate bacteriophages contribute to its virulence and facilitate the dissemination of pathogenicity traits. We isolated a novel siphovirus of the Phietavirus genus, ASZ22RN, derived from a prophage of an S. aureus clonal complex 7 strain and capable of propagating in the prophage-free laboratory strain RN4220. ASZ22RN either productively infected or lysed from without all 47 tested S. aureus clinical strains across 12 clonal complexes (CCs), demonstrating its ability to puncture their cell envelopes. When ASZ22RN was propagated in RN4220 cells harboring an S. aureus-Escherichia coli plasmid replicating via theta mode, it transduced the plasmid to plasmid-free RN4220 with low frequency. The transduction frequency increased by nearly five orders of magnitude when the plasmid contained a fragment of ASZ22RN DNA ( terS ). Most terS+ plasmid-transducing particles carried plasmid concatamers, while some carried plasmid-phage DNA hybrids, as demonstrated by DNA sequencing. Strains from all tested CCs served as recipients for transduction, regardless of the presence of type I restriction-modification enzymes targeting plasmid/phage DNA, or prophages with lysis-lysogeny switch regions conferring superinfection immunity to ASZ22RN. Our results indicate that intracellular phage defense systems do not prevent phage-mediated plasmid transfer and demonstrate a simple method for introducing plasmids constructed in E. coli into clinical S. aureus isolates. Moreover, the presence of the ASZ22RN lysis-lysogeny switch region in 21% of tested ASZ22RN-resistant strains highlights superinfection exclusion as a dominant mechanism of resistance to siphoviruses in staphylococci. IMPORTANCE: This study highlights the capacity of a newly isolated staphylococcal Phietavirus , ASZ22RN, to transfer a low-copy-number shuttle Staphylococcus aureus - Escherichia coli plasmid to various S. aureus strains representing major clonal complexes from among clinical isolates. By increasing the plasmid transduction efficiency in an ASZ22RN-specific manner, we show that the primary factor determining a given strain’s ability to be a recipient in transduction is the capacity of transducing phage to puncture the cell envelopes of this strain. This can be determined not only based on productive phage infection but also lysis from without. Major intracellular mechanisms protecting S. aureus from productive phage infection do not impede the transduction-mediated acquisition of plasmids. Moreover, the lack of phage DNA in most of the plasmid-transducing virions indicates the lack of phage contamination in most transductants. Our results offer a promising approach for developing efficient pipelines to introduce plasmids constructed in E. coli to clinical S. aureus isolates.